INmune Bio (NASDAQ:INMB) Trading Up 2% – Time to Buy?

INmune Bio, Inc. (NASDAQ:INMB)’s share price traded up 2% during mid-day trading on Tuesday . The stock traded as high as $1.52 and last traded at $1.50. 236,245 shares traded hands during mid-day trading, a decline of 27% from the average session volume of 325,004 shares. The stock had previously closed at $1.47.

Analysts Set New Price Targets

Several research firms have recently commented on INMB. Wall Street Zen raised INmune Bio from a “sell” rating to a “hold” rating in a report on Sunday, December 14th. Weiss Ratings reiterated a “sell (e+)” rating on shares of INmune Bio in a report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, INmune Bio currently has a consensus rating of “Hold” and an average target price of $18.00.

INmune Bio Price Performance

The firm has a market cap of $39.87 million, a price-to-earnings ratio of -0.71 and a beta of 0.70. The firm’s fifty day moving average is $1.68 and its two-hundred day moving average is $2.01.

INmune Bio (NASDAQ:INMB) last announced its earnings results on Thursday, October 30th. The company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.07. On average, equities analysts forecast that INmune Bio, Inc. will post -2.24 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in INMB. Vanguard Group Inc. grew its holdings in shares of INmune Bio by 3.4% during the third quarter. Vanguard Group Inc. now owns 876,292 shares of the company’s stock worth $1,814,000 after purchasing an additional 28,541 shares during the last quarter. Geode Capital Management LLC boosted its stake in INmune Bio by 6.9% in the 2nd quarter. Geode Capital Management LLC now owns 389,931 shares of the company’s stock worth $901,000 after purchasing an additional 25,069 shares during the period. XTX Topco Ltd grew its stake in shares of INmune Bio by 240.9% during the 2nd quarter. XTX Topco Ltd now owns 125,847 shares of the company’s stock worth $291,000 after acquiring an additional 88,928 shares in the last quarter. Westside Investment Management Inc. increased its position in shares of INmune Bio by 384.0% in the third quarter. Westside Investment Management Inc. now owns 103,450 shares of the company’s stock valued at $214,000 after acquiring an additional 82,075 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its position in INmune Bio by 1,042.7% during the second quarter. JPMorgan Chase & Co. now owns 73,097 shares of the company’s stock worth $169,000 after acquiring an additional 66,700 shares in the last quarter. Institutional investors own 12.72% of the company’s stock.

INmune Bio Company Profile

INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions.

The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.